Biotechnology company Illumina, Inc. (NASDAQ: ILMN) initiated layoffs within its research and development (R&D) team, affecting approximately 10% of that staff.

The upcoming report from Illumina (ILMN) is expected to reveal quarterly earnings of $0.23 per share, indicating a decline of 28.1% compared to the year-ago period. Analysts forecast revenues of ...

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving ...

Illumina, Inc. (NASDAQ:ILMN) Illumina 2024 Strategy Update Special Call August 13, 2024 11:00 AM ETCompany Participants. Salli Schwartz - Head of IR Jacob Thaysen - CEO Steve Barnard - CTO Ankur ...